Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MIMEDX GROUP, INC.

(MDXG)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 12/02 01:49:09 pm
6.905 USD   -0.22%
11/30MIMEDX Announces Speakers for December 7 Investor Day
AQ
11/26Top Premarket Decliners
MT
11/22MIMEDX GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MIMEDX : to Host Third Quarter 2021 Operating and Financial Results Conference Call on November 3

10/20/2021 | 08:01am EST

MARIETTA, Ga., Oct. 20, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, today announced that it will report operating and financial results for the third quarter ended September 30, 2021 after the market close on Tuesday, November 2, 2021. MIMEDX management will host a webcast and conference call to review its results on Wednesday, November 3, 2021, beginning at 8:30 am Eastern Time.

The conference call can be accessed using the following information:

Webcast: Click here
U.S. Investors: 877-407-6184
International Investors: 201-389-0877
Conference ID: 13723750

A replay of the webcast will be available for approximately 30 days on the Company’s website at www.mimedx.com following the conclusion of the event.

About MIMEDX
MIMEDX is an industry leader in utilizing amniotic tissue as a platform for regenerative medicine, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental biologics, we have both a base business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.

Contacts:
Investors
Jack Howarth
404-360-5681
jhowarth@mimedx.com

Corporate Communications
Hilary Dixon
404-323-4779
hdixon@mimedx.com


Primary Logo

Source: MiMedx Group, Inc

2021 GlobeNewswire, Inc., source Press Releases

All news about MIMEDX GROUP, INC.
11/30MIMEDX Announces Speakers for December 7 Investor Day
AQ
11/26Top Premarket Decliners
MT
11/22MIMEDX GROUP, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K..
AQ
11/22MIMEDX to Present at the Piper Sandler 33rd Annual Healthcare Conference
GL
11/17Peer Reviewed Study Demonstrates MIMEDX Dehydrated Human Amnion Chorion Membrane (dHACM..
AQ
11/17Mimedx Group, Inc. Announces Publication of Peer-Reviewed Study in Facial Plastic Surge..
CI
11/02MIMEDX : Q3 Earnings Snapshot
AQ
11/02Year-to-Date Adjusted Net Sales Increase of 16% in Core Portfolio Sales Versus Prior Ye..
PU
11/02Earnings Flash (MDXG) MIMEDX GROUP Posts Q3 Revenue $63.1M, vs. Street Est of $60.3M
MT
11/02MIMEDX Announces Third Quarter 2021áOperating and Financial Results
GL
More news
Analyst Recommendations on MIMEDX GROUP, INC.
More recommendations
Financials (USD)
Sales 2021 254 M - -
Net income 2021 -21,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -35,8x
Yield 2021 -
Capitalization 768 M 768 M -
Capi. / Sales 2021 3,03x
Capi. / Sales 2022 2,77x
Nbr of Employees 735
Free-Float 96,6%
Chart MIMEDX GROUP, INC.
Duration : Period :
MiMedx Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MIMEDX GROUP, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 6,92 $
Average target price 13,83 $
Spread / Average Target 99,9%
EPS Revisions
Managers and Directors
Timothy R. Wright Chief Executive Officer & Director
Peter M. Carlson Chief Financial Officer
M. Kathleen Behrens Wilsey Chairman
David H. Mason Chief Medical Officer
Robert Benjamin Stein Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
MIMEDX GROUP, INC.-23.79%768
MODERNA, INC.197.32%125 937
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE310.30%80 784
WUXI APPTEC CO., LTD.26.13%67 780
REGENERON PHARMACEUTICALS31.76%65 932